Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCT-ANK-11
- Development stage
- Unknown
- Lead developer
- Beijing Kejing Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CCT-ANK-11 is an investigational activated natural killer (ANK) cell therapy developed by Beijing Kejing Biotechnology. The product consists of ex vivo expanded and activated NK cells, which are innate immune effector cells capable of identifying and lysing tumor cells through the release of perforin and granzymes. CCT-ANK-11 is being evaluated in exploratory clinical trials for the treatment of various advanced solid tumors, including lung, liver, and gastric cancers. The therapy is typically administered in combination with standard-of-care treatments to enhance anti-tumor immune responses and overcome immune evasion within the tumor microenvironment.
- Other names
- CCT-ANK-11CCT-ANK11CCT-ANK 11NK cellsActivated Natural Killer cells
Beyond the preview
Go deeper on CCT-ANK-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCT-ANK-11.